UNSPSC 51391901: Dilazep

This classification denotes an alpha-adrenergic agonist with the molecular formula C31H44N2O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F8KLC2BD5Z, chemically known as tetrahydro-1h-1,4-diazepine-1,4(5h)-dipropanol 3,4,5-trimethoxybenzoate (diester) but generally known as dilazep, which bears US NIH Compound Identifier 3074. European Medicines Agency schedules Dilazep in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07144MIG.

UNSPSC 51391901 Dilazep is a Commodity code that shows minimal recent state and local procurement activity directly aligned with its pharmaceutical scope. The code nominally covers a specific vasodilator medication, but recent state and local solicitations tagged under this code involve broader pharmaceutical procurement — primarily naloxone and drug deactivation systems for public health response, and exploratory vendor-capability research for direct-to-manufacturer prescription programs. State and local issuing bodies pursuing pharmaceutical acquisitions under related codes include county health departments and state health and human services commissions. Seminole County, Florida, and the Texas Health and Human Services Commission represent the jurisdictional mix evident in current activity.

Seminole County, Florida posted an IFB on June 30, 2026 (response deadline July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the contract carries a two-year initial term with a one-year renewal option. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would establish direct contracts between the state's pharmacy benefit program and pharmaceutical manufacturers, with responses due April 3, 2026. Geographic activity is concentrated in the Southeast (Florida) and South (Texas), with the Texas RFI representing preliminary market-intelligence collection rather than a formal competitive award mechanism. The mismatch between the code's nominal scope (dilazep) and the actual pharmaceutical work being solicited (naloxone, drug deactivation systems, direct-to-manufacturer prescription programs) suggests that state and local buyers may be applying this code as a catch-all for pharmaceutical procurement outside established specialized categories.